Access to hepatitis C medicines
Hepatitis C is a global epidemic. Worldwide, 185 million people are estimated to be infected, most of whom live in low- and middle-income countries. Recent advances in the development of antiviral drugs have produced therapies that are more effective, safer and better tolerated than existing treatme...
Saved in:
Main Authors: | Danny J Edwards (Author), Delphi GM Coppens (Author), Tara L Prasad (Author), Laurien A Rook (Author), Jayasree K Iyer (Author) |
---|---|
Format: | Book |
Published: |
The World Health Organization,
2015-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Is the pharmaceutical industry improving with regard to access to essential medicines?
by: Hans V Hogerzeil, et al.
Published: (2014) -
Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
by: Tony Antoniou, et al.
Published: (2023) -
Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
by: Tony Antoniou, et al.
Published: (2023) -
Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis
by: Bryony Simmons, MPH, et al.
Published: (2019) -
Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
by: Yibeltal Assefa, et al.
Published: (2017)